Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure: Substudy of the RE-LY trial

Thrombosis and Haemostasis

Volumn 113, Issue 3, 2015, Pages 625-632

  Douketis, James D ^a   Healey, Jeff S ^a,b   Brueckmann, Martina ^c,d   Eikelboom, John W ^a,b   Ezekowitz, Michael D ^e   Fraessdorf, Mandy ^c   Noack, Herbert ^c   Oldgren, Jonas ^f   Reilly, Paul ^g   Spyropoulos, Alex C ^h   Wallentin, Lars ^f   Connolly, Stuart J ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f UPPSALA UNIVERSITY   (Sweden)

^g BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^h NONE   (United States)

Author keywords

Bridging anticoagulation; Dabigatran; Surgery; Warfarin

Indexed keywords

DABIGATRAN; ENOXAPARIN; HEPARIN; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BRIDGING ANTICOAGULATION; CEREBROVASCULAR ACCIDENT; ELECTIVE SURGERY; EMBOLISM; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOEMBOLISM; TREATMENT OUTCOME; ADVERSE EFFECTS; ATRIAL FIBRILLATION; BLOOD LOSS, SURGICAL; COMPLICATION; DRUG ADMINISTRATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; POSTOPERATIVE HEMORRHAGE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; STROKE; SURGERY; TIME;

ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD LOSS, SURGICAL; DABIGATRAN; DRUG ADMINISTRATION SCHEDULE; ELECTIVE SURGICAL PROCEDURES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PERIOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; SURGICAL PROCEDURES, OPERATIVE; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84925307979     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-04-0305     Document Type: Article

References (35)

1. Douketis JD, et al. Perioperative management of antithrombotic therapy: Anti-thrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141: e326S-350S.
2. van Ryn J, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116–1127.
3. Spyropoulos AC, Douketis JD. How i treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012; 120: 2954–2962.
4. Birnie DH, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. New Engl J Med 2013; 368: 2084–2093.
5. Connolly SJ, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009; 361: 1139–1151.
6. Healey JS, et al. Periprocedural bleeding and thromboembolic events with dabi-gatran compared with warfarin: Results from the randomized evaluation of long-term anticoagulation therapy (re-ly) randomized trial. Circulation 2012; 126: 343–348.
7. Granger CB, et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011; 365: 981–992.
8. Patel MR, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011; 365: 883–891.
9. Giugliano R P, et al. Edoxaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2013; 369: 2093–2104.
10. Go AS, et al. Heart disease and stroke statistics--2013 update: A report from the american heart association. Circulation 2013; 127: e6-e245.
11. Stangier J, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study. Clin Pharmacokin 2010; 49: 259–268.
12. Douketis JD, et al. The perioperative management of antithrombotic therapy: American college of chest physicians evidence-based clinical practice guidelines (8th ed.). Chest 2008; 133: 299S-339S.
13. Spyropoulos AC, et al. Periprocedural antithrombotic and bridging therapy: Recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. J Thromb Haemost 2012; 10: 692–694.
14. Gage BF, et al. Validation of clinical classification schemes for predicting stroke: Results from the national registry of atrial fibrillation. J Am Med Assoc 2001; 285: 2864–2870.
15. Levey AS, et al. Definition and classification of chronic kidney disease: A position statement from kidney disease: Improving global outcomes (kdigo). Kidney Int 2005; 67: 2089–2100.
16. Wunsch H, et al. Methods to adjust for bias and confounding in critical care health services research involving observational data. J Crit Care 2006; 21: 1–7.
17. Lip G Y, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010; 137: 263–272.
18. Pisters R, et al. A novel user-friendly score (has-bled) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010; 138: 1093–1100.
19. Omran H, et al. The has-bled score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre bnk online bridging registry (border). Thromb Haemost 2012; 108: 65–73.
20. Schulman S, Crowther MA. How i treat with anticoagulants in 2012: New and old anticoagulants, and when and how to switch. Blood 2012; 119: 3016–3023.
21. Douketis JD. Pharmacologic properties of the new oral anticoagulants: A clinician-oriented review with a focus on perioperative management. Curr Pharma-ceut Design 2010; 16: 3436–3441.
22. Tafur AJ, et al. Predictors of major bleeding in peri-procedural anticoagulation management. J Thromb Haemost 2012; 10: 261–267.
23. Dunn A. Perioperative management of oral anticoagulation: When and how to bridge. J Thromb Thrombol 2006; 21: 85–89.
24. Siegal D, et al. Periprocedural heparin bridging in patients receiving vitamin k antagonists: Systematic review and meta-analysis of bleeding and thromboem-bolic rates. Circulation 2012; 126: 1630–1639.
25. Kovacs MJ, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004; 110: 1658–1663.
26. Dewilde WJ, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 2013; 381: 1107–1115.
27. Kaatz S, et al. Risk of stroke after surgery in patients with and without chronic atrial fibrillation. J Thromb Haemost 2010; 8: 884–890.
28. Harrison RW, et al. To bridge or not to bridge: These are the questions. J Thromb Thrombol 2012; 34: 31–35.
29. Spyropoulos AC, Ortel TL. Antithrombotic therapy and invasive procedures. New Engl J Med 2013; 369: 1078.
30. Skeith L, et al. Device surgery without interruption of anticoagulation. New Engl J Med 2013; 369: 1570–1571.
31. Vanassche T, et al. Heparin bridging in peri-procedural management of new oral anticoagulant: A bridge too far? Eur Heart J 2014; Epub ahead of print.
32. Liew A, Douketis J. Perioperative management of patients who are receiving a novel oral anticoagulant. Intern Emerg Med 2013; 8: 477–484.
33. Healey JS, Brambatti M. Periprocedural management of oral anticoagulation in patients with atrial fibrillation: Approach in the era of new oral anticoagulants. Canad J Cardiol 2013; 29: S54–59.
34. Ferrandis R, et al. The perioperative management of new direct oral anticoagulants: A question without answers. Thromb Haemost 2013; 110: 515–522.
35. Beyer-Westendorf J, et al. Peri-interventional management of novel oral anticoagulants in daily care: Results from the prospective Dresden NOAC registry. Eur Heart J 2014; Epub ahead of print.